Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,466,257

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $79.32 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks News

Luminex (LMNX) Tops Q1 Earnings, Revenue Guidance Raised

Luminex Corporation (LMNX) reported earnings of 27 cents per share in the first quarter of 2017, surpassing the Zacks Consensus Estimate of adjusted earnings of 8 cents per share by a massive 237.5%.

    Cardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y

    Cardinal Health Inc. (CAH) reported third-quarter fiscal 2017 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.46 and increased 7% on a year-over-year basis.

      Hill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2

      Hill-Rom Holdings, Inc. (HRC) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 88 cents, up 23.9% from the year-ago quarter.

        Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates

        Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.

          Is a Surprise in Store for Hologic (HOLX) in Q2 Earnings?

          Hologic Inc. (HOLX) is slated to report second-quarter fiscal 2017 financial results on May 10, after the closing bell.

            Align Technology (ALGN) Beats on Q1 Earnings and Revenues

            Align Technology Inc. (ALGN) reported adjusted earnings per share (EPS) of 85 cents in the first quarter of 2017, up 70% from 50 cents posted in the year-ago quarter.

              athenahealth (ATHN) Misses on Earnings & Revenues in Q1

              athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017, which missed the Zacks Consensus Estimate by a penny.

                Chemed's (CHE) Earnings and Revenues Beat Estimates in Q1

                Chemed Corp.'s (CHE) first-quarter 2017 adjusted earnings per share (EPS) (considering stock-based compensation expense and related tax benefit as a regular one) were $1.92, as compared to the year-ago adjusted EPS figure of $1.52, up 26.3% year over year.

                  Varian Medical (VAR) Beats on Earnings and Revenues in Q2

                  Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 89 cents per share in the second quarter of fiscal 2017, which beat the Zacks Consensus Estimate by a penny.

                    Pacific Biosciences (PACB) Q1 Loss Wider than Estimated

                    Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.

                      Baxter International (BAX) Q1 Earnings Beat, FY17 View Up

                      Baxter International Inc. (BAX) reported first-quarter 2017 adjusted earnings of 58 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents and was way better than the year-ago figure of 36 cents.

                        Baxter Launches Drug Library Guide for Smart Infusion System

                        Baxter International Inc. (BAX) recently introduced an infusion system drug library guide to help clinicians identify potential errors in the infusion process during intravenous treatment.

                          Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown

                          On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG) -- manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories.

                            Quest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View

                            Quest Diagnostics' (DGX) first-quarter 2017 adjusted earnings per share (EPS) of $1.33 came in 13.7% ahead of the Zacks Consensus Estimate.

                              Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device

                              Abbott Laboratories (ABT) reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, up 17.1% year over year.

                                Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues

                                Intuitive Surgical Inc.(ISRG) posted adjusted earnings of $4.67 per share in the first quarter of 2017, crushing the Zacks Consensus Estimate of $3.97 on stellar revenue growth.

                                  Mazor (MZOR) Gets FDA Clearance For Mazor X Align Software

                                  Mazor Robotics Ltd. (MZOR), recently announced that it has received the FDA clearance for its Mazor X Align software.

                                    Quality Systems (QSII) to Acquire Entrada for $34 Million

                                    Quality Systems, Inc. announced that it has entered into a deal to acquire Entrada, Inc. for $34 million.

                                      Mazor Robotics (MZOR) Catches Eye: Stock Moves Up 10.2%

                                      Mazor Robotics Ltd. (MZOR) moved big last session, as its shares rose over 10% on the day.

                                        Hologic (HOLX) Up 3.9% Since Earnings Report: Can It Continue?

                                        Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          Allscripts' (MDRX) dbMotion Solution Available Through Azure

                                          Allscripts Healthcare Solutions, Inc. (MDRX), announced that dbMotion Solution will be now available through Microsoft Corporation's (MSFT) cloud computing service Azure.

                                            Accuray TomoTherapy System Starts Cancer Treatment in Africa

                                            Accuray Inc. (ARAY) recently announced that the Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria has finally initiated cancer treatment with the company's flagship TomoTherapy system.

                                              ResMed's Study Results for Central Sleep Apnea Hold Promise

                                              ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA).

                                                athenahealth (ATHN) Allies with CoverMyMeds for Faster ePA

                                                athenahealth Inc. (ATHN) recently entered into a strategic partnership with CoverMyMeds.

                                                  DaVita Banks on Acquisitions, Escalating Expenses a Concern

                                                  On Apr 10, we issued an updated research report Denver, CO-based DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure.